BlueWillow Issues NIH Grant To Help Lower Chlamydia and Other STI Rates

BlueWillow Issues NIH Grant To Help Lower Chlamydia and Other STI Rates

An NIH Small Busi­ness Inno­va­tion Research grant to BlueWil­low Bio­log­ics recent­ly to devel­op an intranasal vac­cine called NanoVax that could pre­vent chlamy­dia. There are over 131 mil­lion new infec­tions of chlamy­dia every year with no cur­rent vac­cine to help stop the infection. 

Most chlamy­dia cas­es go unre­port­ed or treat­ed because most peo­ple have no symp­toms and don’t feel they need to be test­ed. How­ev­er, untreat­ed chlamy­dia in females can cause a range of health prob­lems such as pelvic inflam­ma­to­ry dis­ease, which leads to irrepara­ble dam­age to the fal­lop­i­an tubes, uterus and tis­sue in the area. PID can also lead to infer­til­i­ty, ectopic preg­nan­cies and con­stant pelvic pain.

BlueWil­low, for­mer­ly called NanoBio Cor­po­ra­tion, was giv­en the one-year Phase 1 SBIR grant by the NIH’s Aller­gy and Infec­tious Dis­eases agency. The grant will fund vivo stud­ies that will com­bine its NanoVax tech­nol­o­gy with Dr. James Mahony’s chlamy­dia anti­gen that he devel­oped at the Hamil­ton, Ontario McMas­ter University. 

Chlamy­dia that goes undi­ag­nosed means patients are not get­ting the antibi­otics they need to treat the infec­tion. Maho­ny said the NanoVax vac­cine coin­cid­ing with the nov­el BD484 anti­gen could stop the infec­tion from tak­ing hold, decreas­ing the num­ber of PID cas­es. With few­er PID cas­es, few­er women suf­fer from infer­til­i­ty and pain and the costs of health­care decreases.

He said the vac­cine could have a sig­nif­i­cant pos­i­tive impact on people’s qual­i­ty of life and their repro­duc­tive health. 

The NanoVax plat­form uses a unique oil-in-water nanoemul­sion that caus­es both a mucos­al and sys­temic immune respons­es that could poten­tial­ly play a key role in stop­ping STIs like chlamydia. 

Accord­ing to ini­tial tests, NanoVax mixed with the mucos­al immu­ni­ty induc­tion and intranasal vac­ci­na­tion has low­ered the risk of both PID and chlamy­dia infec­tions. The grant allows the com­pa­ny to con­tin­ue its research in the hopes that it can offer a pre­ven­tive solu­tion that allows for clin­i­cal trials. 

With a pletho­ra of undi­ag­nosed STIs, BlueWil­low is work­ing hard to come up with solu­tions that address the world­wide health crisis. 


Related Articles
5 Ways People Can Contract the HIV/AIDS Virus
HIV
5 Ways People Can Contract the HIV/AIDS Virus
Researchers believe that the HIV/AIDS virus originally came from the chimpanzees’ simian…
Funding Needed To Combat Rise In Congenital Syphilis Cases
Syphilis
Funding Needed To Combat Rise In Congenital Syphilis Cases
The U.S. Centers for Disease Control and Prevention said over 900 babies born in the states…
Study Finds Individual HPV Types Increases Chances For HIV Transmission
HPV
Study Finds Individual HPV Types Increases Chances For HIV Transmission
A University of California, Riverside scientists along with an international team of…